144 related articles for article (PubMed ID: 38361528)
1. Viral load kinetics and the clinical consequences of cytomegalovirus in kidney transplantation.
Dobrer S; Sherwood KR; Hirji I; Lan J; Gill J; Matic N; Keown PA
Front Immunol; 2023; 14():1302627. PubMed ID: 38361528
[TBL] [Abstract][Full Text] [Related]
2. Impact of belatacept and tacrolimus on cytomegalovirus viral load control and relapse in moderate and high-risk cytomegalovirus serostatus kidney transplant recipients.
Magua W; Johnson AC; Karadkhele GM; Badell IR; Vasanth P; Mehta AK; Easley KA; Newell KA; Rickert JB; Larsen CP
Transpl Infect Dis; 2022 Dec; 24(6):e13983. PubMed ID: 36321801
[TBL] [Abstract][Full Text] [Related]
3. The impact of viral load and time to onset of cytomegalovirus replication on long-term graft survival after kidney transplantation.
Reischig T; Kacer M; Hruba P; Jindra P; Hes O; Lysak D; Bouda M; Viklicky O
Antivir Ther; 2017; 22(6):503-513. PubMed ID: 28091392
[TBL] [Abstract][Full Text] [Related]
4. Unexpected Cytomegalovirus (CMV) Replication Kinetics in CMV Donor-Seropositive, Recipient-Seronegative Liver Transplant Recipients Receiving Preemptive Antiviral Therapy.
Singh N; Winston DJ; Razonable RR; Marshall Lyon G; Silveira FP; Wagener MM; Limaye AP
J Infect Dis; 2022 Feb; 225(3):436-442. PubMed ID: 33755176
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for high level cytomegalovirus viremia in liver transplant recipients and associated outcomes.
Kleiboeker HL; Jorgenson MR; Leverson GE; Rice JP; Saddler CM; Smith JA; Al-Adra D
Transpl Infect Dis; 2022 Aug; 24(4):e13898. PubMed ID: 35780512
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients.
Tan SK; Waggoner JJ; Pinsky BA
J Clin Virol; 2015 Aug; 69():179-83. PubMed ID: 26209403
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
[TBL] [Abstract][Full Text] [Related]
9. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158
[TBL] [Abstract][Full Text] [Related]
10. Levels of anti-CMV antibodies are modulated by the frequency and intensity of virus reactivations in kidney transplant patients.
Iglesias-Escudero M; Moro-García MA; Marcos-Fernández R; García-Torre A; Álvarez-Argüelles ME; Suárez-Fernández ML; Martínez-Camblor P; Rodríguez M; Alonso-Arias R
PLoS One; 2018; 13(4):e0194789. PubMed ID: 29641536
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance.
Lindsay J; Othman J; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Pergam SA; Liu C; Slavin MA; Greenwood M
Transpl Infect Dis; 2021 Jun; 23(3):e13548. PubMed ID: 33342000
[TBL] [Abstract][Full Text] [Related]
12. Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss.
Andrei G; Van Loon E; Lerut E; Victoor J; Meijers B; Bammens B; Sprangers B; Gillemot S; Fiten P; Opdenakker G; Lagrou K; Kuypers D; Snoeck R; Naesens M
Antiviral Res; 2019 Aug; 168():203-209. PubMed ID: 31212020
[TBL] [Abstract][Full Text] [Related]
13. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
14. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.
Favi E; Santangelo R; Iesari S; Morandi M; Marcovecchio GE; Trecarichi EM; Salerno MP; Ferraresso M; Citterio F; Romagnoli J
Transplant Proc; 2017 Oct; 49(8):1766-1772. PubMed ID: 28923622
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus viremia after kidney transplantation in Thailand: predictors of symptomatic infection and outcome.
Watcharananan SP; Louhapanswat S; Chantratita W; Jirasiritham S; Sumethkul V
Transplant Proc; 2012 Apr; 44(3):701-5. PubMed ID: 22483472
[TBL] [Abstract][Full Text] [Related]
16. Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients.
Camargo JF; Kimble E; Rosa R; Shimose LA; Bueno MX; Jeyakumar N; Morris MI; Abbo LM; Simkins J; Alencar MC; Benjamin C; Wieder E; Jimenez A; Beitinjaneh A; Goodman M; Byrnes JJ; Lekakis LJ; Pereira D; Komanduri KV
Biol Blood Marrow Transplant; 2018 Apr; 24(4):806-814. PubMed ID: 29217388
[TBL] [Abstract][Full Text] [Related]
17. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
[TBL] [Abstract][Full Text] [Related]
18. Molecular Detection and Glycoprotein B (UL55) Genotyping of Cytomegalovirus among Sudanese Renal Transplant Recipients.
Ahmed HH; Altyab HN; Saeed SM; Abdalla WM; Omer AE
Biomed Res Int; 2022; 2022():5403694. PubMed ID: 35686228
[TBL] [Abstract][Full Text] [Related]
19. Which CMV viral load threshold should be defined as CMV infection in kidney transplant patients?
Eshraghi H; Hekmat R
Transplant Proc; 2015 May; 47(4):1136-9. PubMed ID: 26036538
[TBL] [Abstract][Full Text] [Related]
20. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
